The In­sti­tute for Clin­i­cal and Eco­nomic Re­view has re­leased a re­port that found No­var­tis’ new heart fail­ure drug En­tresto, which car­ries a sticker price of $4,560, should be dis­counted by 17% to make it cost­ef­fec­tive.

Modern Healthcare - - LATE NEWS -

Although the drug pro­vides a clear ben­e­fit over stan­dard treat­ments, the re­port found, it could im­pose an ex­ces­sive fi­nan­cial bur­den on the U.S. health sys­tem be­cause of its po­ten­tial pa­tient pop­u­la­tion of more than 1.9 mil­lion within its first five years on the mar­ket. ICER re­leased two drug cost analy­ses last week—the first looked at PCSK9 in­hibitors, a new class of in­jectable, choles­terol-low­er­ing drugs that have been listed at an an­nual cost of $14,000. That re­port found that the an­nual cost for Sanofi’s Pralu­ent and Am­gen’s Repatha would have to be low­ered by 82%, to about $2,520, to make them cost-ef­fec­tive.

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.